Business1 min read

STAT+: China moves to restrict foreign biotech acquisitions

By · Via STAT Health · Published by Everything Blog

In short

China has implemented new regulations to restrict foreign acquisitions of biotech companies, emphasizing domestic innovation and aligning with global regulatory standards. The regulations, set to take effect in 2023, require foreign investors to obtain approval from the State Council, including those with a majority stake in Chinese biotech firms. This move is expected to significantly influence the global biotech industry.

Key points

  • China prioritizes domestic innovation and aligns with global regulatory standards.: China prioritizes domestic innovation and aligns with global regulatory standards.
  • The regulations aim to boost domestic biotech companies and align with international stan…: The regulations aim to boost domestic biotech companies and align with international standards.
  • The move is expected to significantly impact the global biotech industry.: The move is expected to significantly impact the global biotech industry.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I might have been just as unblinking as Elizabeth during the three hours of “You Can See Everything.” Seats-edge viewing experience. What did you think?

Also: We’ll be in Madrid later this week for the European Society for Medical Oncology’s annual meeting, and we’ll be penning an ESMO in 30 Seconds newsletter. Sign up here.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Original source: www.statnews.com

Business